Annual Report 2017 The rare disease  champion Shire plc Annual Report 2017 The rare disease champion Shire is the global leader in serving patients with rare diseases. Our vision  is to be an innovation-driven biotech company applying our core scientific  platforms to develop and deliver best-in-class therapies across our  franchises in Immunology, Hematology, Neuroscience, Internal Medicine,  Genetic Diseases, Oncology and Ophthalmics. We focus on diseases  and patient populations with the highest unmet needs and use our global  infrastructure to reach people in more than 100 countries who  are struggling to live their lives to the fullest. Commercial spotlight:  Launch excellence Technology spotlight:  Intersection of health and technology  to enable patient-centric care  Franchise spotlight:  Immunology Pipeline spotlight:  SHP643 for Hereditary Angioedema (HAE) Strategic report At a glance 2  Chairman’s review 4 Chief Executive Officer’s review 6 Key industry trends 10 Our business model 12 Our strategy 14 Key performance indicators 16 Principal risks and uncertainties 18 In-line products 22 Pipeline programs 24 Pipeline spotlight 26 Commercial spotlight 28 Technology spotlight 30 Franchise spotlight 32 Responsibility 35 Review of our business 44 Governance Board of Directors 56 Executive Committee 59 Chairman’s governance statement 60 Board and committee governance 62 Audit, Compliance & Risk Committee 71 Nomination & Governance Committee 75 Science & Technology Committee 77 Directors’ remuneration report 78 Additional governance information 109 Directors’ responsibilities statements 113 Financial statements Independent auditor’s report 114 Consolidated balance sheets 121 Consolidated statements of operations 122 Consolidated statements of  comprehensive income  123 Consolidated statements of changes in equity 124 Consolidated statements of cash flows 126 Notes to the consolidated financial statements 128 Other information Non GAAP measures 179 Shareholder information 184 Cautionary statements 186 Risk factors 187 Shire plc report and financial statements 199 Trademarks 217  See page 26  See page 28  See page 30  See page 32 Lynsey  Living with HAE Read more   on page 27  1 Shire Annual Report 2017 At a glance The leader in   rare diseases Global reach 40+ Marketed products 100 Plasma collection centers  100+ Countries where our  therapies are available 14 Manufacturing sites 100+ Relationships with   patient advocacy  organizations 60+ Commercial presence  in 60+ countries Group headquarters:   Dublin, Ireland Commercial hub:  Zug, Switzerland Innovation and  commercial hub:  Cambridge, MA 57%  North America 36%  Europe 5%  Asia 2%  Latin America Employment by region 23,044 64%  United States 36%  International Revenue by region $15.2bn 2 Shire Annual Report 2017 Product sales Immunology $4,370m Hematology $3,786m Neuroscience $2,664m Internal Medicine $1,670m Genetic Diseases $1,438m Oncology $262m Ophthalmics $259m 7 10 15 7 8 Registration 2017 approvals Phase 3 Phase 2 Phase 1 We have 40 programs   in our clinical R&D pipeline Our portfolio covers   seven therapeutic areas Immunology Hematology Neuroscience Internal Medicine Genetic Diseases Oncology Ophthalmics Financial highlights 2017 2016 1 Growth 1 Product sales $14,449 million $10,886 million 33% Total revenues $15,161 million $11,397 million 33% Non GAAP Total revenues 2 $15,086 million $11,397 million 32% Operating income from continuing operations $2,455 million $963 million 155% Non GAAP operating income 3 $5,997 million $4,417 million 36% Net income margin 4,5 28% 3% 25ppc Non GAAP EBITDA margin 5,6 43% 41% 2ppc Net income $4,272 million $327 million 1,205% Non GAAP Net income 7 $4,604 million $3,391 million 36% Diluted earnings per ADS 8 $14.05 $1.27 1,006% Non GAAP diluted earnings per ADS 8,9 $15.15 $13.10 16% Net cash provided by operating activities $4,257 million $2,659 million 60% Non GAAP free cash flow 10 $3,431 million $2,103 million 63% 1  Results include Baxalta Inc. (Baxalta) (from the date of acquisition on June 3,  2016) and Dyax Corp. (Dyax) (from the date of acquisition on January 22, 2016). 2  This is a Non GAAP financial measure. The most directly comparable   measure under U.S. GAAP is Total revenues (FY 2017: $15,161m). 3  This is a Non GAAP financial measure. The most directly comparable   measure under U.S. GAAP is Operating Income from continuing operations   (FY 2017: $2,455m). 4  U.S. GAAP Net income as a percentage of total revenues. 5 Percentage point change (ppc)..